HLS Therapeutics (TSE:HLS) Rating Increased to Strong-Buy at Raymond James Financial

HLS Therapeutics (TSE:HLS) was upgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a report released on Friday,BayStreet.CA reports. The firm presently has a C$8.00 price objective on the stock, up from their previous price objective of C$7.00. Raymond James Financial’s price objective points to a potential upside of 104.60% from the company’s current price.

Separately, Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Strong Buy” and a consensus target price of C$8.00.

HLS Therapeutics Price Performance

Shares of HLS stock traded up C$0.04 on Friday, reaching C$3.91. The company had a trading volume of 14,905 shares, compared to its average volume of 22,297. The stock has a market capitalization of C$122.29 million, a PE ratio of -12.22 and a beta of -0.18. The company has a quick ratio of 1.01, a current ratio of 1.00 and a debt-to-equity ratio of 75.00. HLS Therapeutics has a one year low of C$3.77 and a one year high of C$5.77. The business’s 50-day moving average is C$4.23 and its 200 day moving average is C$4.41.

HLS Therapeutics (TSE:HLS) last released its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. The company had revenue of C$14.67 million for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.During the same period last year, the company posted ($0.09) EPS. Equities research analysts forecast that HLS Therapeutics will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.